293 related articles for article (PubMed ID: 26211396)
1. Adalimumab for the treatment of pediatric Crohn's disease.
Nuti F; Fiorino G; Danese S
Expert Rev Clin Immunol; 2015; 11(9):963-72. PubMed ID: 26211396
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of Adalimumab in Crohn's disease].
Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
[TBL] [Abstract][Full Text] [Related]
3. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
4. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
[TBL] [Abstract][Full Text] [Related]
5. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
6. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
[TBL] [Abstract][Full Text] [Related]
7. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
9. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
11. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
13. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
14. Optimizing biological therapy in Crohn's disease.
Gecse KB; Végh Z; Lakatos PL
Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
16. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
Lichtiger S; Binion DG; Wolf DC; Present DH; Bensimon AG; Wu E; Yu AP; Cardoso AT; Chao J; Mulani PM; Lomax KG; Kent JD
Aliment Pharmacol Ther; 2010 Nov; 32(10):1228-39. PubMed ID: 20955442
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
